Abstract
To evaluate the efficacy and safety of chemoradiation therapy with docetaxel, fluorouracil, and nedaplatin for the patients with esophageal cancer and simultaneous double primary malignancy. Three patients with inoperable disease were enrolled to receive the combination of docetaxel 40mg/m2 (on days 1 and 21), nedaplatin 10mg/body (on days 1∼5 and 21∼25), and fluorouracil 350mg/m2 (on days 1∼5 and 21∼25) with radiation (60Gy in 2-Gy fractions over 6 weeks). Evaluated responses were a complete response in 1 patient and partial responses in 2 pateints. The overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%). This chemoradiation therapy is effective for and well-tolerable by patients with esophageal cancer and simultaneous double primary malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
